

1 **Marker-free imaging of α -Synuclein aggregates in a rat model of**
2 **Parkinson's disease using Raman microspectroscopy**

3
4 Fide Sevgi^{1#}, Eva M Brauchle^{1,2,3#}, Daniel A Carvajal Berrio^{1,3}, Katja Schenke-
5 Layland^{1,2,3,4}, Nicolas Casadei⁵, Madhuri S Salker¹, Olaf Riess⁵, Yogesh Singh^{1,5*}

6
7 ¹Department of Women's Health, Research Institute for Women's Health, Eberhard
8 Karls Tübingen University, Tübingen, Germany

9 ²NMI Natural and Medical Sciences Institute at the Tübingen University, Reutlingen,
10 Germany

11 ³Cluster of Excellence iFIT (EXC 2180) "Image-Guided and Functionally Instructed
12 Tumor Therapies", Eberhard Karls University Tübingen, Tübingen, Germany

13 ⁴Department of Medicine/Cardiology, Cardiovascular Research Laboratories, David
14 Geffen School of Medicine at UCLA, Los Angeles, CA, USA

15 ⁵Institute of Medical Genetics & Applied Genomics, Eberhard Karls Tübingen
16 University, Tübingen, Germany

17
18
19 #Equal contributions

20
21
22 *Address for correspondence:

23
24 Dr Yogesh Singh
25 Institute of Medical Genetics and Applied Genomics,
26 Eberhard Karls Tübingen University,
27 Calwerstraße 7, 72076, Germany
28 Phone: 0049 7071 29 78264
29 Email: yogesh.singh@med.uni-tuebingen.de

30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48

49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89

Abstract

A hallmark of Parkinson's disease (PD) is the formation of Lewy bodies in the brain. Lewy bodies are rich in the aggregated form of misfolded α -Synuclein (α -Syn). The brain from PD patients can only be analysed after post-mortem, limiting the diagnosis of PD to the manifestation of motor symptoms. In PD patients and animal models phosphorylated α -Syn was detected in the gut, thus, raising the hypothesis that early-stage PD could be diagnosed based on colon tissues biopsies. Non-invasive marker-free technologies represent an ideal method to potentially detect aggregated α -Syn *in vivo*. Raman microspectroscopy has been established for the detection of molecular changes such as alterations of protein structures. Here, the olfactory bulb in the brain and the muscularis mucosae of colon tissue sections of a human BAC-SNCA transgenic (TG) rat model was analysed using Raman imaging and microspectroscopy. Raman images from TG and WT rats were investigated using spectral, principal component and true component analysis. Spectral components indicated protein aggregates (spheroidal oligomers) in TG rat brain and colon tissues even at a young age but not in WT. In summary, we have demonstrated that Raman imaging is capable to detect α -Syn aggregates in colon tissues of a PD rat model and making it a promising tool for future use in PD pathology.

90
91
92
93
94

95 Introduction

96
97
98
99
100
101
102
103

Parkinson's disease (PD) is the second most common disorder among neurodegenerative diseases with 6.1 million persons afflicted worldwide as estimated in 2016 (1, 2). This disease burden is projected to have doubled in the past 25 years, while the number of older people did not increase in the same amount, indicating environmental factors could have an important role in PD progression (2). PD is manifested by the loss of neurons in the *substantia pars nigra compacta* with an increased neural loss of up to 70% by the time of death (3).

104
105
106
107
108
109
110
111
112

The presence of Lewy bodies (LB) represents the pathological hallmark of PD, as they were linked to the death of the dopamine producing cells in the brain (4). The major component of LB is the filamentous inclusion protein α -Synuclein (α -Syn) (5). Accurate process of *in vivo* LB formation is not known. However, it is widely accepted that aggregation of α -Syn into soluble oligomers and then insoluble amyloid fibrils is the foundation of LB (6). During the aggregation process, phosphorylation is a usual characteristic as post-translational phosphorylation of α -Syn is observed in 90% of misfolded proteins, while in cytosolic α -Syn only 4% is phosphorylated (7). Even though α -Syn is an abundant protein in the brain, its exact function remains elusive.

113
114
115
116
117
118
119
120
121
122
123
124

In its natively unfolded nature, α -Syn is a monomeric or intrinsically disordered protein in neuronal cells and highly conserved protein and mostly found in the presynaptic terminals of neurons and possibly in the nucleus (5, 8, 9). However, α -Syn adopts an α -helical nature upon engaging with lipid membranes and detergent micelles (10, 11). Nuclear magnetic resonance (NMR) studies also demonstrated that the N-terminal region of the protein had a tendency towards forming stable α -helical secondary structures (12, 13). Further, *in vitro* studies suggested that monomeric α -Syn was consisting mostly of α -helical (49%) and extended β -strand and polyproline II (PPII) structures (41%) with only a small amount of β -sheet present (10%) (14). Different phenotypes of PD may be connected to polymorphism of fibrils, as it has been described earlier that the fibrils may have different subtypes (9). While the mature fibrils are known to be toxic for the cells, however, in recent years the intermediate species have been highlighted as even more neurotoxic (5, 15-17).

125
126
127
128
129
130
131
132
133
134
135

Many of the non-motor symptoms are associated with impaired peripheral nervous system or the peripheral part of the central nervous system (vagus nerve, olfactory bulb, etc.) (18, 19). The receptor neurons of the olfactory bulb are exposed directly to the environmental, giving an interface where environmental factors could trigger α -Syn aggregation (19). For α -Syn aggregation to occur, the enteric neurons (axons of myenteric plexus and/or submucosal plexus) needed to be triggered by an intrinsic or environmental factor (20). Recent study highlighted that enteroendocrine cells (EECs) were directly linked to enteric neurons, and therefore to the brain through the gastrointestinal muscles and the vagus nerve (21). Further, EECs also contained native α -Syn naturally, thus, these cells at the interface between environmental toxins and the enteric nervous system might be the source of the aggregation (21, 22). Several earlier studies supported a notion that the prion-like propagation of the α -

136 Syn aggregation from cell to cell (19, 23-26). Interestingly, α -Syn aggregates also be found
137 inside gastrointestinal nerves, from oesophagus to the rectal end, before they can be
138 observed in any of the dopamine producing neurons (27). A direct transportation of α -Syn,
139 injected into enteric neurons, towards the brain through the vagus nerve is demonstrated in
140 several animal models, however, bidirectional propagation of α -Syn is possible (28-31).

141 Raman microspectroscopy is an ideal technology for the use in medical and biochemical
142 studies because of a high sensitivity and marker-free application (12, 32). Raman spectra
143 indicate changes of protein secondary structure based on specific peak shifts (11).
144 Previously, Raman microspectroscopy was utilized in mouse model of AD for tau plaques
145 from the murine brain (33, 34). Further, Raman spectroscopy was used for detection of α -
146 Syn aggregations in vitro studies (9, 10). However, none of the findings described either
147 human PD patient or rodent models to our knowledge. Thus, we hypothesized Raman
148 microspectroscopy could be utilized to recognize α -Syn forms, either native or aggregations,
149 and their current structure in the fibrillization process to gain an insight into the progression of
150 PD from gut to brain.

151 In this study, we used BAC-SNCA transgenic rats (TG) expressing full length non-mutated
152 human α -Syn (35) and control wild-type (WT) rats at different ages [4 months (4M) and 12M]
153 to investigate the effects of ageing and the differences between normal and pathological
154 tissues due to expression of human α -Syn in the colon. Using Raman imaging and
155 microspectroscopy together with immunofluorescence staining we detected the presence of
156 α -Syn aggregated proteins and confirmed changes in the protein secondary structures due to
157 the fibrillization process in the brain and the colon tissues.

158 **Material and Methods**

159 **Animals used for the study**

160 The BAC-SNCA transgenic (TG) rats were described earlier (35) and corresponding age and
161 sex matched wildtype (WT) rats (Sprague Dawley outbred genetic background) were used
162 for this study. All the rats were kept in standard open type IV cages (3-4 rats/cage) under a
163 12 h light-dark cycle with *ad libitum* access to food pellet and water. All experiments were
164 performed according to the EU Animals Scientific Procedures Act and the German law for
165 the welfare of animals. All procedures were approved (TVA: HG3/18) by the authorities of the
166 state of Baden-Württemberg.

167 **Colon and brain sample preparation**

168 The brain and colon tissues of WT and TG rats aged 4M or 12M were used for this study.
169 The tissues were frozen in O.C.T. compound and stored at -80°C until sectioning. Before
170 sectioning tissues were acclimatized at -20°C . A cryotome was used to cut tissue sections of
171 $10\ \mu\text{m}$ thickness, which were collected on standard glass slides. For the colon tissues 2-3
172 sections per slide were collected, while for the brain tissues one section per slide was
173 collected. Eventually, 25 slides were collected for each sample. The remaining whole animal
174 tissues were embedded into O.C.T. for protection and transported to the -80°C freezer. The
175 tissue sections were stored in the -20°C freezer until further processing (details of chemical
176 used in the study are available in Suppl. Table 1).

177 **Hematoxylin and Eosin staining**

178 Hematoxylin and eosin staining (H&E) was performed on selected colon tissues (slide
179 number 5, 19, 15, 20, 25) for morphological evaluation of the tissue sections and the
180 identification of the area of interest. The tissue sections were washed three times with DPBS-
181 for 5 minutes. Then, the sections were fixed with 4% PFA for 15 minutes and washed again
182 with DPBS for 15 minutes. The sections were then treated with hematoxylin solution for 9
183 minutes and afterwards with demineralized water for a few seconds. A microscope was used
184 to examine if the staining was sufficient. Next, the sections were left under running warm
185 water for 10 minutes to wash away excessive staining and briefly washed with demineralized
186 water for a few seconds. Afterwards, the sections were treated with eosin solution for 2
187 minutes, before being treated with demineralized water again for a few seconds. Then, the
188 samples were put through a dehydration procedure of 70% ethanol (EtOH), 90% EtOH and
189 100% EtOH for 5 minutes each (details of chemical used in the study are available in Suppl.
190 Table 1). Next, the sections were washed with isopropanol for 5 minutes twice. The sections
191 were then mounted with isomount and covered with a thin glass slide. Afterwards the
192 sections were scanned with the slide scanner.

193 **Nissl staining**

194 Nissl staining was performed on selected brain tissues (slide number 5, 19, 15, 20, 25) for
195 differentiation of the different brain regions, and to detect if the sections were intact enough
196 for further processing. The sections were washed three times with DPBS for 5 minutes. If no
197 more O.C.T. could be observed, the tissues were fixed with 4% PFA for 15 minutes and
198 washed again with DPBS for 15 minutes. The sections were then treated with 1% cresyl
199 violet solution for 10 minutes and afterwards with demineralized water for a few seconds
200 (details of chemical used in the study are available in Suppl. Table 1). Next, a microscope
201 was used to examine if the staining was sufficient. Afterwards, the samples were dehydrated
202 analogously to H&E staining and washed twice with isopropanol for 5 minutes and mounted
203 with isomount before being covered with a thin glass slide. Afterwards the sections were
204 scanned with the slide scanner.

205 **Immunofluorescence staining**

206 Immunofluorescence staining was performed at least once per samples so that the alpha-
207 synuclein expressing regions could be identified. The primary and secondary antibodies were
208 used for the staining (Suppl. Table 2). It was performed either with a single primary and a
209 single secondary antibody or with two primary and two secondary antibodies.

210 The following procedure of antibody staining was modified slightly from the protocol
211 previously established (36). The sections were placed into tubic racks and washed twice with
212 DPBS for 10 minutes, and fixed with 4% PFA for 20 minutes, before being washed again with
213 DPBS twice for 5 minutes. The unspecific binding sites were blocked with goat blocking
214 buffer. Next, the samples were treated with primary antibodies for an hour. After a washing
215 step with the washing buffer, the samples were treated with the secondary antibody for 30
216 minutes in a dark room at room temperature. Afterwards, another washing step was
217 performed. If the samples were going to be measured directly with the Raman micro-
218 spectrometer, the process was stopped, and the sections were stored in DPBS in a dark
219 container for further use. If the samples were going to be just imaged with the fluorescence
220 microscope, the samples were treated with DAPI for 10 minutes and after a washing step,
221 the sections were mounted with prolong gold antifade mounting media (Thermofisher).

222 A control sample was always processed alongside the immunofluorescence staining for the
223 evaluation of the staining success and the evaluation of unspecific background staining. The
224 previous procedure was performed with the exception that instead of diluting the primary
225 antibodies in the dilution buffer, the dilution buffer was used on its own. Afterwards the
226 stained samples could be compared with the controls.

227 **Imaging of immunofluorescence-stained sections with observer microscope**

228 The sections stained with DAPI were examined with the Observer fluorescence microscope
229 (Zeiss GmbH, Germany). The 10x, 20x and 40x objectives were used, where with the 40x
230 objective an immersion oil had to be applied to the samples. The microscopy was performed
231 at a wavelength of 358 nm (DAPI, blue channel), 488 nm (green channel) and 594 nm (red
232 channel). The software Zeiss Zen Blue Edition was used for the evaluation and processing of
233 the images (Suppl. Table 3 and 4).

234 **Raman imaging and microspectroscopy**

235 ***System set-up and sample preparation***

236 A commercial Raman microspectroscopy system (Alpha300R, WITec, Ulm) was used for all
237 Raman measurements as previously described in detail (37, 38). The samples examined
238 were either untreated colon samples or immunofluorescence-stained colon or brain samples.
239 All samples were kept in DPBS before and during the Raman measurements.

240 First brain then colon samples were treated through immunofluorescence staining; therefore,
241 three of the six measured areas were selected from stained regions while the other three
242 were selected randomly from non-stained regions. The large area scan width to height was
243 50 μm x 50 μm , the points per line and lines per image of the scan were 100 and 100,
244 making the scan step size 0.5 μm . The integration time was selected as 0.5 seconds. A
245 fluorescence image and a bright field image of the same area were overlapped to identify the
246 immunofluorescence-stained area. In addition, single spectra were measured for later
247 analysis. 12 measurements were taken for the stained regions and 12 measurements for the
248 non-stained regions within one sample, with 10 accumulations and an accumulation time of
249 10 seconds.

250 The untreated colon sections were measured by selecting three randomized areas in the
251 muscularis externa. The large area scan width to height was 50 μm x 100 μm , the points per
252 line and lines per image of the scan were 100 and 200, making the scan step size 0.5 μm .
253 The integration time was selected as 0.5 seconds. The immunofluorescence-stained colon
254 sections were measured with the same parameters, but stained regions were specifically
255 selected for the measurements. A fluorescence image and the bright field image of the same
256 sample area were overlapped to identify the stained area. Additionally, 15 single spectra
257 were measured for each sample in stained regions for later analysis, with 10 accumulations
258 and an accumulation time of 10 seconds.

259 ***Pre-Treatment of the Spectra***

260 For later statistical analysis, the spectra were pre-treated with the Project Five software
261 (WITec, Ulm, Germany; Suppl. Table 4). Cosmic rays were removed. Next, the background
262 was subtracted from the spectra using a shape correction method and a shape of 150.
263 Therefore, the baseline was similar in all spectra and therefore comparable. The spectra

264 were then normalized, with the normalization type area to 1. Large area scans were stitched
265 together so later they could be analyzed together.

266 ***Raman imaging and spectral analysis***

267 Raman data were analyzed through different methods to detect differences in the samples at
268 different time-points (4 months or 12 months) or at a different modification (TG or WT).

269 The spectra (overall average of the Raman images of all the samples in each group) of the
270 different groups (4M WT & TG and 12M WT & TG) were then compared to each other to
271 identify differences. The ratio of different peaks from amide I and amide III bands were
272 compared. The compared peaks were phenylalanine (1004 cm⁻¹)/amide III - β -sheet (1267
273 cm⁻¹), phenylalanine (1004 cm⁻¹)/amide III - α -helix (1298 cm⁻¹), phenylalanine (1004 cm-
274 1)/amide III - α -helix (1340 cm⁻¹), phenylalanine (1004 cm⁻¹)/amide I - α -helix (1658 cm⁻¹),
275 amide III - β -sheet (1267 cm⁻¹)/amide III - α -helix (1298cm⁻¹), amide III - β -sheet (1267 cm-
276 1)/amide III - α -helix (1340cm⁻¹) and amide III - β -sheet (1267 cm⁻¹)/amide I - α -helix
277 (1658cm⁻¹). The statistical analysis through t-test was performed with Microsoft Excel 365.

278 ***Principal component analysis (PCA)***

279 Single spectra data were uploaded to Unscrambler X 10.5 to perform principal component
280 analysis (PCA). The different sample groups were analyzed with seven principal components
281 (PC) as described previously (37, 38). The results were presented in a score plot explained
282 by two PCs. For each PC, a loading plot was obtained, where the scores were explained
283 through spectra. The results from different groups were compared statistically through t-test
284 with Microsoft Excel 365. The PCs with statistical significance and best separation were
285 selected.

286 ***True component analysis (TCA)***

287 True component analysis (TCA, Project Plus Software, WITec) was used to analyse Raman
288 images as previously described in detail (37, 38). For the colon samples, the analysis was
289 performed in the whole area (intensity range of the pixels: 0-1) or in the stained regions
290 (intensity range of the pixels: 0-0.8).

291 ***Statistics***

292 For spectral analysis, PCA and TCA Raman images/scans were used (Suppl. Fig. 1a, b and
293 Suppl. Table 4). The samples were measured and separated into four group: 4M WT, 4M
294 TG, 12M WT and 12M TG. The single spectra of the different groups were compared to each
295 other to identify the difference between sample groups. Further, the intensity and the full
296 width at half maximum (FWHM) of the spectra were statistically analysed based on a t-test or
297 one-way analysis of variance (ANOVA).

298

299 **Results**

300 ***Identification of endogenous α -Syn aggregation in the brain olfactory bulb region of*** 301 ***TG rats***

302 To identify the accumulation of α -Syn aggregation in the TG brain, we used the olfactory bulb
303 brain regions as it is an early site of α -Syn accumulation (39, 40). The brain sections were
304 used for Nissl staining for the confirmation that the area of interest was suitable for the
305 Raman measurements (Suppl. Fig. 1a, b). We detected endogenous rat-specific α -Syn faintly
306 in the whole brain region of either WT or TG but predominantly on the edges (Fig. 1a). The α -
307 Syn stained area was used for the measurement by Raman microspectroscopy (Suppl. Fig.
308 1b). After measurement of the samples, the assignment of the peaks was identified for
309 comparable results found in the literature (Suppl. Fig. 1c, Suppl. Table 5).

310 First, we compared Raman spectra of WT and TG genotypes at 12M age. We can observe
311 the visible differences for the peaks 879 cm^{-1} (hydroxyproline), 1063 cm^{-1} (C-C skeletal
312 stretch), 1265 cm^{-1} (amide III, β -sheet), 1298 cm^{-1} (amide III, α -helix), 1450 cm^{-1} (CH_2 , CH_3
313 deformation) and the amide I shoulders 1586 cm^{-1} (C=C olefinic stretch) and 1606 cm^{-1} (C=C
314 phenylalanine stretch). Based on all the biological samples ($n=3$) for 12M TG rat brains had a
315 higher intensity than the 12M WT rat brains ($n=4$) except on the amide I shoulders, where
316 WT rat brains have more intensity (Fig. 1a). At 1450 cm^{-1} , the peak produced a shoulder at
317 1441 cm^{-1} in the 12M TG rat brains, while it was totally absent in the 12M WT rat brains, this
318 could be due to polarization effect. We found that intensity of the 759 cm^{-1} , 830 cm^{-1} , 877 cm^{-1} ,
319 1268 cm^{-1} (amide III, β -sheet) and 1298 cm^{-1} (amide III, α -helix) peaks were significantly
320 different between WT and TG rat brains (Fig. 1b, Suppl. Fig. 2). Significant differences were
321 present when spectral peak data were normalized in the 1004 cm^{-1} (phenylalanine) to 1267
322 cm^{-1} (amide III, β -sheet) ratio and the 1004 cm^{-1} (phenylalanine) to 1298 cm^{-1} (amide III, α -
323 helix) ratio (Fig. 1c). Further, significant difference was also noticed when spectral peak data
324 were normalized in the 1267 cm^{-1} (amide III, β -sheet) to 1340 cm^{-1} (amide III, α -helix) ratio
325 and the 1267 cm^{-1} (amide III, β -sheet) to 1658 cm^{-1} (amide I, α -helix) ratio (Fig. 1c).

326 **Genotype comparison for PCA**

327 The Raman spectra of 12M WT & TG brains were compared to each other through PCA to
328 identify differences between the genotypes. A statistically significant separation was
329 achieved in the fingerprint region of the PC-6 and PC-7 score values (both PCs explained
330 1% of the variance) (Fig. 1d). It was possible to detect the separation as most of the WT 12M
331 samples were on the positive region, while most of the TG 12M samples were on the
332 negative region (Fig. 1d, upper panel). The prominent peaks present on PC-7 and PC-6
333 loadings were shown in Fig. 1d, lower panel and Suppl. Fig. 3 respectively. Two Beta sheets
334 were present in 12M TG rats compared with WT, while 12M WT rats have more alpha helix
335 and beta-stranded and PP II than 12M TG rat brain.

336 **Brain genotype comparison using Raman imaging**

337 The area of interest for Raman imaging was identified *via* α -Syn immunofluorescence
338 staining. In Raman images from all samples four major spectral components were identified:
339 lipids, cell nuclei, matrix and an unknown component (Fig. 2). The measured representative
340 regions from 12M WT and TG along with the separated components are shown in Fig. 2b.
341 No significant difference was observed in cell nuclei and unknown component except some

342 visible difference in matrix and significant difference in lipids (Fig. 3). Lipids appeared to be
343 more solid in the TG rat brain with less space in between than the WT brain samples (Figure
344 2c). Further, in the lipid component, intensity statistical significant differences were detected
345 at 873 and 1175 cm^{-1} (Tyrosine) between 12M WT compared with 12M TG (Fig. 3 a,c).
346 However, some visible differences were also observed 1439 and 1083 cm^{-1} , though it did not
347 reach to a significance level (Fig. 3 a,c). Similarly, matrix component in the brain region was
348 appeared to different at 1209, 1589 (C=C olefinic stretching) cm^{-1} peaks and some visibly
349 different (Fig. 3 b,d). Taken together, we concluded that TG rat brain samples have different
350 property compared to WT brain samples.

351 ***Identification of endogenous α -Syn aggregation in the colon of TG rats***

352 After establishing the spectral pattern in the brain, we focussed on the colon region with the
353 predicted α -Syn aggregations could be present in TG rats. After the measurement of the
354 samples with the Raman micro-spectroscopy, the assignments of the peaks were identified
355 for comparable results as described in the brain samples (Fig. 4a). For spectral analysis and
356 PCA, single spectra were measured while for TCA, large area scans were used (Suppl. Fig.
357 1c, d).

358 First, we made the genotype comparisons between 4M WT and TG colon samples using
359 spectral analysis (Fig. 4b). A clear visible difference was identified in 879 cm^{-1}
360 (hydroxyproline), 1093 cm^{-1} (phosphodioxo group), 1248 cm^{-1} (amide III, β -Sheet), 1317 cm^{-1}
361 (amide III, α -helix) and 1342 cm^{-1} (amide III, α -helix). Only, the intensity of the 1317 cm^{-1}
362 (amide III, α -helix) peak was statistical different between 4M WT and TG colon (Fig. 4b). The
363 chosen peaks were from amide I or amide III divided with each other and also to
364 phenylalanine (1004 cm^{-1}), significant differences were detected at 1003 cm^{-1} (phenylalanine)
365 to 1317 cm^{-1} (amide III, α -helix) ratio (Fig. 4c). Further, 12M WT and TG samples were
366 analysed. Visible differences were observed in the 855 cm^{-1} (tyrosine), 879 cm^{-1}
367 (hydroxyproline), 938 cm^{-1} (proline), 1096 cm^{-1} (phosphodioxo group), 1248 cm^{-1} (amide III,
368 β -Sheet), 1317 cm^{-1} (amide III, α -helix) and 1402 cm^{-1} (C=O stretch) (Fig. 4a). The 12M TG
369 colon samples were more intense in every marked area except the 1317 cm^{-1} peak.
370 However, statistically significant differences were observed in the FWHM of the 1128 cm^{-1}
371 peak (Suppl. Fig. 4a).

372 Further ageing comparisons were made among 4M and 12M TG colon samples. The 12M
373 TG colon sample peaks were more intense in every marked area except the 827 cm^{-1} peak
374 and the two α -helix peaks of amide III (1299 cm^{-1} and 1342 cm^{-1}) where, as identified in
375 previous sections, a change in intensity was observed at the β -sheet to α -helix turning point.
376 Statistically differences were observed in the intensities of the 829 cm^{-1} , 855 cm^{-1} , 939 cm^{-1} ,
377 1004 cm^{-1} and 1158 cm^{-1} peaks (Suppl. Fig. 4b). No statistical difference was observed in 4M
378 and 12M WT rat colon samples (Fig. 4a,c). Thus, our spectral data highlight that ageing
379 could have an important change in the colon tissue composition of the TG rats based on
380 peak intensities.

381 ***PCA analysis to identify the aggregation of α -Syn in the TG colons***

382 The 4M TG/WT samples were compared to each other through PCA to identify the
383 differences through the modification of rats at the same age. The PCA of the fingerprint
384 region was analysed. Significant separation was observed at the PC-4 score values, which
385 explained 8% of the variance, as the other PCs did not show differences. The separation at

386 PC- 4 was easily distinguishable, with the WT 4M samples mostly on the negative region and
387 the TG 4M samples mostly on the positive region (Suppl. Fig. 4c). The most prominent
388 peaks were 1001 cm^{-1} (phenylalanine) and 1321 cm^{-1} (amide III α -helix) on the positive
389 region (4M TG) and 787 cm^{-1} (DNA) and 1378 cm^{-1} (T, A, G) on the negative region (4M
390 WT). Most of the major peaks in the negative region were related to DNA.

391 Furthermore, in amide I, a significant separation was achieved through the PC-2 score
392 values, which explained 8% of the variance and the PC-7 score values, which explained <1%
393 of the variance (Suppl. Fig. 4d). The loadings for PC-2 showed the peaks 1637 cm^{-1} (β
394 sheet) and 1685 cm^{-1} (turn) on the positive region and 1586 cm^{-1} (C=C olefinic stretch) and
395 1606 cm^{-1} (C=C phenylalanine stretch) on the negative region. The loadings for PC-7
396 showed the peaks 1630 cm^{-1} (β sheet) and 1654 cm^{-1} (α -helix) on the positive region and
397 1638 cm^{-1} (β sheet) and 1670 cm^{-1} (extended β -strand and polyproline II (PPII) structures)
398 on the negative region. In amide III, a significant separation was achieved through PC-1
399 score values, which explained 41% of the variance and PC-4 score values, which explained
400 7% of the variance (Suppl. Fig. 4d). The loadings at PC-1 showed the peaks 1294 cm^{-1} (α -
401 helix) and 1340 cm^{-1} (α -helix) on the positive region and the peak 1245 cm^{-1} (β sheet) with
402 the shoulder 1270 cm^{-1} (α -helix) on the negative region.

403 The 12M TG and WT samples were compare to each other through PCA to identify
404 differences of modified rats at the same age (12M). PCA of fingerprint region did not show
405 any difference among WT and TG rat samples. The amide I and amide III regions were
406 analysed closer with separate PCAs. In amide III, a significant separation was achieved
407 through the PC-6 score values, which explained 1% of the variance. The loadings of PC-6
408 showed 1262 cm^{-1} (β -sheet) and 1310 cm^{-1} (α -helix) on the positive region and 1296 cm^{-1}
409 (α -helix) on the negative region (Suppl. Fig. 5a). In amide I, a significant separation was
410 achieved through the PC-4 score values, which explained 3% of the variance (Fig. 4d). The
411 separation at PC-4 was overlapping, but recognizable. The 12M TG samples were more on
412 the positive region, while the 12M WT samples were more on the negative region (Fig. 4d).
413 The most significant PC-4 was visualized with PC-2 with their corresponding loadings (Fig.
414 4d). The loadings of PC-4 showed the peak 1635 cm^{-1} (β -sheet) on the positive region and
415 the peaks 1578 cm^{-1} (nucleic acids) and 1658 cm^{-1} (α -helix).

416 Further, ageing comparisons were made in TG rats (4M vs 12M) samples through PCA to
417 identify the differences among TG colon samples with ageing. Significant separation was
418 detected at the PC-2 score values (25% of the variance), at the PC-3 score values (15% of
419 the variance) and at the PC-4 score values (11% of the variance) (Suppl. Fig. 5b). The most
420 significant PC-4 was visualized with PC-2 with their corresponding loadings (Suppl. Fig. 5b).
421 12M TG samples were more on the positive region and the TG 4M samples were more on
422 the negative region. The separation at PC-2 was less clear but distinguishable with the TG
423 12M samples more on the positive region and the TG 4M samples more on the negative
424 region. The major peaks on PC-2 were 860 cm^{-1} (phosphate group), 940 cm^{-1} (proline), 1248
425 cm^{-1} (amide III, β - sheet), 1653 cm^{-1} (amide III, α -helix) and 1685 cm^{-1} (amide I, turn) on the
426 positive region and 1065 cm^{-1} (C-C skeletal stretch), 1086 cm^{-1} (phosphodioxy group), 1130
427 cm^{-1} (C-C acyl backbone), 1296 cm^{-1} (amide III, α -helix) and 1439 cm^{-1} (CH_2 and CH_3
428 deformation) on the negative region. The loadings of PC-4 contained the main peaks 1637
429 cm^{-1} (β sheet) and 1673 cm^{-1} (extended β -strand and PPII structures) on the positive region
430 and the peaks 1001 cm^{-1} (phenylalanine) and 1315 cm^{-1} (amide III, α -helix) and on the
431 negative region.

432 The amide I and amide III regions were analysed further in detail with separate PCAs (Suppl.
433 Fig. 5c). In amide I, a significant separation was achieved through the PC-2 score values,
434 which explained 10% of the variance, the PC-3 score values, which explained 6% of the
435 variance and the PC-5 score values, which explained 2% of the variance (Fig. 4e). The
436 separation was clearer with PC-5, where the TG 12M samples were more on the positive
437 region, while the TG 4M samples were mostly in the negative region. The loadings for PC-2
438 showed the major peaks 1634 cm⁻¹ (β sheet), 1668 cm⁻¹ (β -sheet) and 1683 cm⁻¹ (turn) on
439 the positive region and the peak 1605 cm⁻¹ (C=C phenylalanine stretch) on the negative
440 region (Suppl. Fig. 5c). The loadings for PC-5 showed the major peaks 1576 cm⁻¹ (nucleic
441 acids), 1632 cm⁻¹ (β sheet) and 1669 cm⁻¹ (β -sheet) on the positive region and 1606 cm⁻¹
442 (C=C phenylalanine stretch) and 1658 cm⁻¹ (α -helix) on the negative region (Fig. 4e). In
443 summary, 12M TG contained higher amount of β -sheet compared with 4M TG, while 4M TG
444 contained advanced intermediate oligomers and more α -helices.

445 **TCA analysis to detect other cell components with ageing in TG rat colon**

446 Every measured sample with Raman microspectroscopy was also subjected to TCA. We
447 stained the colon tissues with α -Syn staining (D37A6) antibody to achieve the proper results
448 for the TCA and only antibody positive stained region was used. (Fig. 5a, b).

449 Raman images showed that collagen fibers surrounded the α -Syn-stained regions in all the
450 samples with a more intense appearance in the older rats, presumably increasing in
451 thickness with age (Fig. 5c). Lipids appeared to be more concentrated in the stained regions
452 with no changes in intensities between genotypes (Fig. 5d). The colon unknown component
453 appeared more solid in the α -Syn stained regions, possibly showing a connection with the
454 protein. The intensity was lower in the WT 4M region, with no visible changes in the other
455 groups (Fig. 5e). The cells were mostly observed in the non-stained regions in all animals
456 except the 4M WT sample, where cells were also observed inside the stained area (Fig. 5f).
457 The cells in the TG groups appeared smaller, possibly in the process of apoptosis. The
458 muscle fibers were concentrated in the regions surrounding the staining, with no visible
459 changes in intensity between the groups (Fig. 5g). The spectral components of TCA were
460 separated into their respective groups (4M WT, 4M TG, 12M WT and 12M TG). The spectra
461 particularizing the same component were averaged and graphed together so that the
462 differences of the groups in the same component could be visualized (Suppl. Fig. 6).

463 After the extraction of the different components through TCA (collagen fibers, lipids, unknown
464 component, cells and muscle fibers) the CCD counts and the number of pixels were scaled
465 to an interval where all the positive pixels were contained. From the CCD count and the
466 pixels, an intensity was calculated. The averaged intensity per pixel was taken for each
467 component in each group to detect any difference between the components when their
468 intensity in the TCA was compared. After statistical analysis, changes were observed in the
469 muscle fibers between 4M and 12M TG as well as nearly significant among 4M WT and TG
470 colon samples (Suppl. Fig. 6). Other components were not significantly different (data not
471 shown).

472 Furthermore, the averaged intensities per pixel were taken for the components stained with
473 α -Syn antibody (D37A6), in the regions where the staining was observed. A significant
474 difference was also observed at 4M age among WT and TG for collagen fibers (Fig. 6a-b).

475 Additionally, statistical differences were observed at the unknown component between 12M
476 WT and TG as well as for 4M WT and TG colon samples (Fig. 6c).

477 Further, the fluorescence microscope was used to display stained tissue sections for α -Syn
478 and collagen fibers surrounding the α -Syn-stained regions (Fig. 6d). In 12M TG, pockets
479 between the α -Syn and collagen fibers were observed (Fig. 6d). Cells (based on DAPI
480 staining) were abundant in the surrounding regions but absent in the stained regions,
481 occurring between adjacent collagen fibers shielding (Fig. 6d). In the 4M TG rats no
482 unstained areas were observed between the α -Syn and the collagen fibers. Morphologically,
483 cells differed from the surrounding cells outside the stained region, being smaller in size and
484 shorter in length (Fig. 6d). Further, we stained the TG colon tissues using phospho- α -Syn
485 antibody along with total alpha-Syn protein. This analysis revealed that in 12M TG colon
486 tissue phosphorylation/aggregation is mostly located in the pocket region compared with 4M
487 TG rat colon samples (Fig. 6e). Thus, explains that pocket region between the total α -Syn
488 and collagen regions could be due to aggregated α -Syn in older TG rats. Overall, our Raman
489 imaging and microspectroscopy data revealed that ageing could be involved in aggregation
490 of α -Syn in the colon TG rats.

491 Discussion

492 Based on the notion that the beginning of the aggregation process in the colon, α -Syn protein
493 molecules infect the neurons in a prion-like manner, propagating up the vagus nerve towards
494 midbrain, where it causes PD (5, 28, 30, 41). Therefore, aggregation of the proteins and
495 changes in protein conformation was expected in younger rats in the colon, while a
496 progressed disease was probable in older TG rats. We confirmed the presence of
497 aggregated proteins, detected changes in the secondary structure of the proteins due to the
498 fibrillization process, and identified the changes in colon tissues through a combination of
499 Raman imaging and Raman microspectroscopy.

500 Our brain data suggested that signs of the fibrillization process was detected TG rats.
501 Furthermore, the 12M TG rats contained dominantly β -sheet rich secondary structures, signs
502 of an advanced PD with protofibrils and mature fibrils. TCA analysis further revealed changes
503 in lipid structures. This was significant as native α -Syn is known to bind naturally to lipids,
504 making lipid molecules a reflection of α -Syn molecules. Changes in the secondary structures
505 of lipids indicate an effect of α -Syn aggregation and points towards native α -Syn being
506 present in the TG rats.

507 While we used the olfactory bulb region in the brain (42) as the control against colon for our
508 experiments, we believe it is still an acceptable control for the progression of PD in the brain
509 as a 90% correlation between Lewy pathology in the olfactory bulb and *substantia nigra* in
510 midbrain was described (43). Previously, it was detected behavioural difference reminiscent
511 of progressive PD, with an early alteration of olfaction already in 3M TG rats (35). Olfactory
512 bulb was easy to differentiate with other brain regions clearly. Further, the direct connection
513 of the olfactory bulb with the midbrain regions also contribute to similar progression of
514 pathology between the brain regions, making the olfactory bulb a reflection of the *substantia*
515 *nigra* in most instances.

516 In colon, 4M TG rats showed a more advanced aggregation than brain as β -sheets were
517 detected in higher numbers. The presence of additional α -helices and extended β -strands
518 and PPII structures pointed towards an early fibrillization process, making protofibrils

519 unlikely. Additionally, 12M TG rats on the other hand were rich in β -sheets, indicating
520 advanced PD in the colon, could reflect the non-motor symptoms. TCA analysis and
521 fluorescence microscopy images revealed that collagen fibers were surrounding the α -Syn
522 stained regions. Averaged intensity/pixel showed that WT rats contained more collagen
523 fibers, whereas in 12M TG rats the collagen fibers were likely destroyed due to inflammatory
524 mediatory or direct effects of α -Syn. The unknown component of colon was present in α -Syn
525 containing regions of WT rats, linking it to the native protein as well as cell death which was
526 detected in the 12M TG rats.

527 No compelling signs of aggregation were observed in the colon in rats of any age in the WT
528 samples, while less advanced fibrillization, possibly misfolded monomers or early spheroidal
529 oligomers were detected in 12M WT samples in the brain, α -Syn aggregation could begin in
530 advanced ages even in healthy individuals with a starting point of olfactory bulb, but not
531 colon. As previously described (44), the failure of the UPS and LAS pathways are a likely
532 cause of α -Syn aggregation in 12M WT rats. The lack of fibrillization in the colon support this
533 theory, as the failure of UPS and LAS systems were only described in the brain but not in the
534 enteric nervous system, indicating environmental factors as the more likely trigger in α -Syn
535 aggregation in the colon such as gut bacterial dysbiosis (45). In the 4M TG group, the colon
536 showed signs of a more advance fibrillization than brain, where a higher number of α -helices
537 were detected, supporting several researchers, who illustrated the colon to brain path of the
538 aggregation through the vagus nerve (27, 28, 30). These results confirmed the prion-like
539 propagation hypothesized by Braak *et. al.*(46) with the enteroendocrine cells as the possible
540 route between the lumen and the enteric nervous system (21).

541 The results were able to successfully confirm the presence of α -Syn aggregations in the
542 colon enteric nervous system. Additionally, a more advanced fibrillization process was
543 identified in colon of 4M TG rats, confirming the hypothesis of this study, where the
544 fibrillization process starts in the colon before advancing towards the brain. In 12M older rats
545 both regions showed signs of advanced fibrillization. Nevertheless, the limitations of the
546 study should be noted for the next experiments, making the results possibly clearer. This is
547 especially true for the antibody staining, where human aggregation specific α -Syn antibody
548 would have been preferred. It should be noted that according to literature, the intermediate
549 oligomers between monomers and fibrils were suspected to be the toxic agent, rather than
550 the mature fibrils, marking the importance of study into the intermediate species, and priority
551 of reversing the fibrillization process rather than slowing it down. The 4M TG group, where
552 most of the intermediate species were present might therefore be in the period of most
553 neuronal damage.

554 Future studies are required to understand all the unknown aspects. More time points (early
555 or late stages of disease) in the rats would be of advantage to pinpoint the starting point of
556 the aggregations more accurately. The measurement of several more brain regions, or even
557 the vagus nerve, would be necessary to understand the further progression of the disease.
558 As previously mentioned, aggregation-specific α -Syn antibodies and a larger sample size
559 would have given more certain results.

560 In the future, Raman microspectroscopy could be a routine tool to detect PD disease in
561 advance through analysis of colon biopsies with a considerable reduced misdiagnosis rate,
562 leading to better care and life quality of the diseased.

563 **Declarations**

564 **Ethics statement and approval**

565 All the experiments were performed according to the EU Animals Scientific Procedures Act
566 (2010/63/EU) and the German law for the welfare of the animals. All the procedure and
567 methods were approved by the local government authorities (Regierungspräsidium,
568 Tübingen; TVA HG3/18) of the state of Baden-Württemberg, Germany.

569 **Consent for publication**

570 No patients or human data used in this study. All authors read the manuscript and approved
571 to be co-authors on the manuscript and have substantial contribution in the manuscript.

572 **Availability of data and material**

573 The datasets used and/or analysed during the current study are available from the
574 corresponding authors on a reasonable request.

575 **Competing interests**

576 The authors declare that they have no competing interests.

577 **Funding**

578 This research project is an EU Joint Programme - Neurodegenerative Disease Research
579 (JPND) (JPCOFUND_FP-829-047 aSynProtect) and is supported through the funding
580 organization Deutschland, Bundesministerium für Bildung und Forschung (BMBF, FKZ).
581 Funders have no role in the study design and data analysis.

582 **Acknowledgements**

583 We acknowledge support by Deutsche Forschungsgemeinschaft (DFG) and Open Access
584 Publishing Fund of the University of Tübingen.

585 **Author's contribution**

586 EMB, YS: Study design, performed the research and managed the overall project, involved in
587 entire study, analyzed the data, made the figures, and wrote the manuscript

588 FS: Performed the experiments, data analysis, made the figures, wrote the manuscript

589 DACB: performed the experiments and data analyses

590 KSL, NC, MSS, OR: provided tools, data analyses and discussions, funding generation and
591 edited the manuscript

592 **Figure legends**

593 **Figure 1.** Spectral comparison in 12M WT and TG olfactory bulb regions. (a) The spectra of
594 WT and TG olfactory bulb regions. (b) All the marked changes were from the statistical 12M
595 WT and TG intensity comparison based on Student's unpaired t-test. Differences were
596 detected in the 759 cm⁻¹ (p=0.04), 830 cm⁻¹ (p=0.02), 877 cm⁻¹ (p=0.04), 1268 cm⁻¹
597 (p=0.008) and 1298 cm⁻¹ (p=0.01) peaks. P value represents *(p ≤0.05), **(p ≤0.01). (c) The

598 ratio of different peaks from amide I and amide III were compared with Student's unpaired t-
599 test to identify statistical changes. Differences were detected in the phenylalanine/amide III -
600 β -sheet ($p=0.001$), phenylalanine/amide III - α -helix ($p=0.04$), amide III - β -sheet/amide III -
601 α -helix ($p=0.009$) and amide III - β -sheet/amide I - α -helix ($p=0.03$). P value represents *(p
602 ≤ 0.05), **($p \leq 0.01$). (d) Comparison of genotype (12M WT and TG) samples through PCA
603 with scores and loadings for the brain sample. The 12M WT and TG 12M samples were
604 compared with PCA of PC-6 and PC-7. Both PC-6 ($p=0.03$) and PC-7 ($p=0.006$) were
605 significant (upper panel). The loadings of PC-6 were visualized (lower panel). Positive side
606 WT while negative side TG brain samples.

607 **Figure 2.** TCA of selected areas in the olfactory bulb of WT and TG animals. (a) The
608 measured area was shown in red boxes. (b) The combined image of the components was
609 shown. (c) The separated components through TCA were lipids in green, (d) an unknown
610 component in orange, (e) cells in blue, and (f) extracellular matrix components in yellow. The
611 CCD count interval was listed for all the components.

612 **Figure 3.** Estimation of lipids and extracellular matrix components in the olfactory bulb
613 region.

614 The components displaying the same results were put together and averaged in their groups.
615 The two components (lipids and extracellular matrix) out of five were appeared to be different
616 in most samples. (a) lipids and (b) extracellular matrix component spectra from WT and TG
617 brain olfactory bulb region. X-axis represents the wavelength in cm^{-1} while y-axis shows the
618 spectral intensity. The separated groups were 12M WT (green) and 12M TG (brown). (c)
619 Differences in the lipid component were observed for intensity at 873 cm^{-1} ($p=0.009$) and
620 1175 ($p=0.006$) between 12M WT and TG based on Student's unpaired t-test and data
621 shown as a Heatmap. (d) Heatmap represents the extracellular matrix component, some
622 apparent difference in the spectra; however, it did not reach to a significance level. P value
623 represents *($p \leq 0.05$), **($p \leq 0.01$).

624 **Figure 4.** Spectral comparison at the genotype and age of the WT and TG rat colons. (a)
625 The spectra of WT and TG colon samples at 4 and 12M age. (b) Differences were detected
626 at the intensity at 4M age for WT and TG in the 1317 cm^{-1} ($p=0.01$) peak. (c) The ratio of
627 different peaks from amide I and amide III were compared with Student' unpaired t-test to
628 identify statistical changes. Differences were detected in the phenylalanine/amide III - α -helix
629 ratio ($p=0.01$). P value represents *($p \leq 0.05$). (d) Comparison of the amide I 12M TG vs. WT
630 samples through PCA with scores and loadings in colon. Amide I samples were compared
631 with PCA at PC-2 and PC-4 (upper panel). PC-4 was significant ($p=0.01$). The loadings of
632 amide I PC-4 were visualized (lower panel). (e) Comparison of the amide I between 4M and
633 12M TG samples through PCA with scores and loadings in colon. Both PC-2 ($p=0.00003$)
634 and PC-5 ($p=0.004$) were significant (upper panel). The loadings of amide I, PC-5 were
635 visualized (lower panel).

636 **Figure 5.** TCA of selected areas in the colon of WT and TG rats. (A) The measured area was
637 shown in red boxes. (B) The combined image of the components was shown. (C) The
638 separated components through TCA were collagen fibers in red, (D) lipids in green, (E)
639 unknown component in orange, (F) cells in blue and (G) muscle fibers in yellow. The CCD
640 count interval was listed for all the components.

641 **Figure 6.** Collagen fibers and an unknown component in the TG rat colon. (a) Combined
642 representative TCA images of the stained regions. The components were collagen fibers
643 (red), lipids (green), an unknown component (orange), cells (blue) and muscle fibers (yellow).
644 The intensity range was scaled 0-0.8 for all components. (b,c) The bar diagram showed the
645 collagen intensity/pixel average for WT and TG rat colon samples at 4M and 12M age.
646 Averaged intensities per pixel of the collagen fibers and unknown component statistically
647 compared using Student's unpaired t-test. P value represents * $p \leq 0.05$. Significant
648 differences were observed in the unknown component between 12M WT and TG ($p=0.002$)
649 as well as between 4M WT and TG 4M ($p=0.03$). In contrary, statistical difference was
650 observed in the collagen fibers only for 4M WT and TG ($p=0.02$). P value represents *(p
651 ≤ 0.05), **($p \leq 0.01$). (d) Staining of the colon tissues with α -Synuclein (green, D37A6),
652 collagen I (red, 113M4774) antibodies and DAPI for cell nucleus for 4M and 12M TG rats. (e)
653 The detection of phospho- α -Synuclein (p129; green) and α -Synuclein (red, D37A6) and DAPI
654 (blue) in the colon tissues of 4M and 12M TG rats.

655 References

- 656 1. G. Alves, E. B. Forsaa, K. F. Pedersen, M. Dreetz Gjerstad and J. P. Larsen:
657 Epidemiology of Parkinson's disease. *J Neurol*, 255 Suppl 5, 18-32 (2008)
658 doi:10.1007/s00415-008-5004-3
- 659 2. E. R. Dorsey, A. Elbaz, E. Nichols, F. Abd-Allah, A. Abdelalim, J. C. Adsuar, M. G.
660 Ansha, C. Brayne, J.-Y. J. Choi, D. Collado-Mateo, N. Dahodwala, H. P. Do, D. Edessa, M.
661 Endres, S.-M. Fereshtehnejad, K. J. Foreman, F. G. Gankpe, R. Gupta, G. J. Hankey, S. I.
662 Hay, M. I. Hegazy, D. T. Hibstu, A. Kasaeian, Y. Khader, I. Khalil, Y.-H. Khang, Y. J. Kim, Y.
663 Kokubo, G. Logroscino, J. Massano, N. Mohamed Ibrahim, M. A. Mohammed, A.
664 Mohammadi, M. Moradi-Lakeh, M. Naghavi, B. T. Nguyen, Y. L. Nirayo, F. A. Ogbo, M. O.
665 Owolabi, D. M. Pereira, M. J. Postma, M. Qorbani, M. A. Rahman, K. T. Roba, H. Safari, S.
666 Safiri, M. Satpathy, M. Sawhney, A. Shafieesabet, M. S. Shiferaw, M. Smith, C. E. I. Szoeki,
667 R. Tabarés-Seisdedos, N. T. Truong, K. N. Ukwaja, N. Venketasubramanian, S. Villafaina, K.
668 g. weldegwergs, R. Westerman, T. Wijeratne, A. S. Winkler, B. T. Xuan, N. Yonemoto, V. L.
669 Feigin, T. Vos and C. J. L. Murray: Global, regional, and national burden of Parkinson's
670 disease, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016.
671 *The Lancet Neurology*, 17(11), 939-953 (2018) doi:10.1016/s1474-4422(18)30295-3
- 672 3. M. R. Cookson: alpha-Synuclein and neuronal cell death. *Mol Neurodegener*, 4, 9
673 (2009) doi:10.1186/1750-1326-4-9
- 674 4. L. A. Munishkina, C. Phelan, V. N. Uversky and A. L. Fink: Conformational behavior
675 and aggregation of alpha-synuclein in organic solvents: modeling the effects of membranes.
676 *Biochemistry*, 42(9), 2720-30 (2003) doi:10.1021/bi027166s
- 677 5. L. V. Kalia and S. K. Kalia: alpha-Synuclein and Lewy pathology in Parkinson's
678 disease. *Curr Opin Neurol*, 28(4), 375-81 (2015) doi:10.1097/WCO.0000000000000215
- 679 6. S. H. Shahmoradian, A. J. Lewis, C. Genoud, J. Hench, T. E. Moors, P. P. Navarro,
680 D. Castano-Diez, G. Schweighauser, A. Graff-Meyer, K. N. Goldie, R. Sutterlin, E. Huisman,
681 A. Ingrassia, Y. Gier, A. J. M. Rozemuller, J. Wang, A. Paepe, J. Erny, A. Staempfli, J.
682 Hoernschemeyer, F. Grosseruschkamp, D. Niedieker, S. F. El-Mashtoly, M. Quadri, I. W. F.
683 J. Van, V. Bonifati, K. Gerwert, B. Bohrmann, S. Frank, M. Britschgi, H. Stahlberg, W. D. J.
684 Van de Berg and M. E. Lauer: Lewy pathology in Parkinson's disease consists of crowded
685 organelles and lipid membranes. *Nat Neurosci*, 22(7), 1099-1109 (2019)
686 doi:10.1038/s41593-019-0423-2
- 687 7. W. S. Kim, K. Kagedal and G. M. Halliday: Alpha-synuclein biology in Lewy body
688 diseases. *Alzheimers Res Ther*, 6(5), 73 (2014) doi:10.1186/s13195-014-0073-2
- 689 8. J. Li, V. N. Uversky and A. L. Fink: Effect of familial Parkinson's disease point
690 mutations A30P and A53T on the structural properties, aggregation, and fibrillation of human
691 alpha-synuclein. *Biochemistry*, 40(38), 11604-13 (2001) doi:10.1021/bi010616g

- 692 9. J. D. Flynn, R. P. McGlinchey, R. L. Walker, 3rd and J. C. Lee: Structural features of
693 alpha-synuclein amyloid fibrils revealed by Raman spectroscopy. *J Biol Chem*, 293(3), 767-
694 776 (2018) doi:10.1074/jbc.M117.812388
- 695 10. C. Mensch, A. Konijnenberg, R. Van Elzen, A.-M. Lambeir, F. Sobott and C.
696 Johannessen: Raman optical activity of human α -synuclein in intrinsically disordered, micelle-
697 bound α -helical, molten globule and oligomeric β -sheet state. *Journal of Raman*
698 *Spectroscopy*, 48(7), 910-918 (2017) doi:10.1002/jrs.5149
- 699 11. N. C. Maiti, M. M. Apetri, M. G. Zagorski, P. R. Carey and V. E. Anderson: Raman
700 spectroscopic characterization of secondary structure in natively unfolded proteins: alpha-
701 synuclein. *J Am Chem Soc*, 126(8), 2399-408 (2004) doi:10.1021/ja0356176
- 702 12. G. Devitt, K. Howard, A. Mudher and S. Mahajan: Raman Spectroscopy: An
703 Emerging Tool in Neurodegenerative Disease Research and Diagnosis. *ACS Chem*
704 *Neurosci*, 9(3), 404-420 (2018) doi:10.1021/acscchemneuro.7b00413
- 705 13. D. Eliezer, E. Kutluay, R. Bussell, Jr. and G. Browne: Conformational properties of
706 alpha-synuclein in its free and lipid-associated states. *J Mol Biol*, 307(4), 1061-73 (2001)
707 doi:10.1006/jmbi.2001.4538
- 708 14. M. M. Apetri, N. C. Maiti, M. G. Zagorski, P. R. Carey and V. E. Anderson: Secondary
709 structure of alpha-synuclein oligomers: characterization by raman and atomic force
710 microscopy. *J Mol Biol*, 355(1), 63-71 (2006) doi:10.1016/j.jmb.2005.10.071
- 711 15. J. C. Bridi and F. Hirth: Mechanisms of alpha-Synuclein Induced Synaptopathy in
712 Parkinson's Disease. *Front Neurosci*, 12, 80 (2018) doi:10.3389/fnins.2018.00080
- 713 16. N. Bengoa-Vergniory, R. F. Roberts, R. Wade-Martins and J. Alegre-Abarategui:
714 Alpha-synuclein oligomers: a new hope. *Acta Neuropathol*, 134(6), 819-838 (2017)
715 doi:10.1007/s00401-017-1755-1
- 716 17. S. A. Yang, J. Yoon, K. Kim and Y. Park: Measurements of morphological and
717 biophysical alterations in individual neuron cells associated with early neurotoxic effects in
718 Parkinson's disease. *Cytometry A*, 91(5), 510-518 (2017) doi:10.1002/cyto.a.23110
- 719 18. C. Pellegrini, R. Colucci, L. Antonioli, E. Barocelli, V. Ballabeni, N. Bernardini, C.
720 Blandizzi, W. J. de Jonge and M. Fornai: Intestinal dysfunction in Parkinson's disease:
721 Lessons learned from translational studies and experimental models. *Neurogastroenterol*
722 *Motil*, 28(12), 1781-1791 (2016) doi:10.1111/nmo.12933
- 723 19. S. Y. Liu, P. Chan and A. J. Stoessl: The underlying mechanism of prodromal PD:
724 insights from the parasympathetic nervous system and the olfactory system. *Transl*
725 *Neurodegener*, 6, 4 (2017) doi:10.1186/s40035-017-0074-8
- 726 20. S. Holmqvist, O. Chutna, L. Bousset, P. Aldrin-Kirk, W. Li, T. Bjorklund, Z. Y. Wang,
727 L. Roybon, R. Melki and J. Y. Li: Direct evidence of Parkinson pathology spread from the
728 gastrointestinal tract to the brain in rats. *Acta Neuropathol*, 128(6), 805-20 (2014)
729 doi:10.1007/s00401-014-1343-6
- 730 21. R. Chandra, A. Hiniker, Y. M. Kuo, R. L. Nussbaum and R. A. Liddle: alpha-Synuclein
731 in gut endocrine cells and its implications for Parkinson's disease. *JCI Insight*, 2(12) (2017)
732 doi:10.1172/jci.insight.92295
- 733 22. R. A. Liddle: Parkinson's disease from the gut. *Brain Res*, 1693(Pt B), 201-206 (2018)
734 doi:10.1016/j.brainres.2018.01.010
- 735 23. N. P. Visanji, P. L. Brooks, L. N. Hazrati and A. E. Lang: The prion hypothesis in
736 Parkinson's disease: Braak to the future. *Acta Neuropathol Commun*, 1, 2 (2013)
737 doi:10.1186/2051-5960-1-2
- 738 24. P. Desplats, H. J. Lee, E. J. Bae, C. Patrick, E. Rockenstein, L. Crews, B. Spencer, E.
739 Masliah and S. J. Lee: Inclusion formation and neuronal cell death through neuron-to-neuron
740 transmission of alpha-synuclein. *Proc Natl Acad Sci U S A*, 106(31), 13010-5 (2009)
741 doi:10.1073/pnas.0903691106
- 742 25. N. Candelise, M. Schmitz, F. Llorens, A. Villar-Pique, M. Cramm, T. Thom, S. M. da
743 Silva Correia, J. E. G. da Cunha, W. Mobius, T. F. Outeiro, V. G. Alvarez, M. Banchelli, C.
744 D'Andrea, M. de Angelis, S. Zafar, A. Rabano, P. Matteini and I. Zerr: Seeding variability of
745 different alpha synuclein strains in synucleinopathies. *Ann Neurol*, 85(5), 691-703 (2019)
746 doi:10.1002/ana.25446


- 747 26. M. Schweighauser, M. Bacioglu, S. K. Fritsch, D. R. Shimshek, P. J. Kahle, Y. S.
748 Eisele and M. Jucker: Formaldehyde-fixed brain tissue from spontaneously ill α -synuclein
749 transgenic mice induces fatal α -synucleinopathy in transgenic hosts. *Acta Neuropathologica*,
750 129(1), 157-159 (2014) doi:10.1007/s00401-014-1360-5
- 751 27. A. Lionnet, L. Leclair-Visonneau, M. Neunlist, S. Murayama, M. Takao, C. H. Adler, P.
752 Derkinderen and T. G. Beach: Does Parkinson's disease start in the gut? *Acta Neuropathol*,
753 135(1), 1-12 (2018) doi:10.1007/s00401-017-1777-8
- 754 28. C. Challis, A. Hori, T. R. Sampson, B. B. Yoo, R. C. Challis, A. M. Hamilton, S. K.
755 Mazmanian, L. A. Volpicelli-Daley and V. Gradinaru: Gut-seeded alpha-synuclein fibrils
756 promote gut dysfunction and brain pathology specifically in aged mice. *Nat Neurosci* (2020)
757 doi:10.1038/s41593-020-0589-7
- 758 29. N. Uemura, H. Yagi, M. T. Uemura, Y. Hatanaka, H. Yamakado and R. Takahashi:
759 Inoculation of alpha-synuclein preformed fibrils into the mouse gastrointestinal tract induces
760 Lewy body-like aggregates in the brainstem via the vagus nerve. *Mol Neurodegener*, 13(1),
761 21 (2018) doi:10.1186/s13024-018-0257-5
- 762 30. L. Volpicelli-Daley and P. Brundin: Prion-like propagation of pathology in Parkinson
763 disease. *Handb Clin Neurol*, 153, 321-335 (2018) doi:10.1016/B978-0-444-63945-5.00017-9
- 764 31. N. Van Den Berge, N. Ferreira, H. Gram, T. W. Mikkelsen, A. K. O. Alstrup, N.
765 Casadei, P. Tsung-Pin, O. Riess, J. R. Nyengaard, G. Tamguney, P. H. Jensen and P.
766 Borghammer: Evidence for bidirectional and trans-synaptic parasympathetic and sympathetic
767 propagation of alpha-synuclein in rats. *Acta Neuropathol*, 138(4), 535-550 (2019)
768 doi:10.1007/s00401-019-02040-w
- 769 32. E. Brauchle and K. Schenke-Layland: Raman spectroscopy in biomedicine - non-
770 invasive in vitro analysis of cells and extracellular matrix components in tissues. *Biotechnol J*,
771 8(3), 288-97 (2013) doi:10.1002/biot.201200163
- 772 33. R. Michael, A. Lenferink, G. Vrensen, E. Gelpi, R. I. Barraquer and C. Otto:
773 Hyperspectral Raman imaging of neuritic plaques and neurofibrillary tangles in brain tissue
774 from Alzheimer's disease patients. *Sci Rep*, 7(1), 15603 (2017) doi:10.1038/s41598-017-
775 16002-3
- 776 34. M. Ji, M. Arbel, L. Zhang, C. W. Freudiger, S. S. Hou, D. Lin, X. Yang, B. J. Bacskai
777 and X. S. Xie: Label-free imaging of amyloid plaques in Alzheimer's disease with stimulated
778 Raman scattering microscopy. *Sci Adv*, 4(11), eaat7715 (2018) doi:10.1126/sciadv.aat7715
- 779 35. S. Nuber, F. Harmuth, Z. Kohl, A. Adame, M. Trejo, K. Schonig, F. Zimmermann, C.
780 Bauer, N. Casadei, C. Giel, C. Calaminus, B. J. Pichler, P. H. Jensen, C. P. Muller, D.
781 Amato, J. Kornhuber, P. Teismann, H. Yamakado, R. Takahashi, J. Winkler, E. Masliah and
782 O. Riess: A progressive dopaminergic phenotype associated with neurotoxic conversion of
783 alpha-synuclein in BAC-transgenic rats. *Brain*, 136(Pt 2), 412-32 (2013)
784 doi:10.1093/brain/aws358
- 785 36. E. Brauchle, J. Kasper, R. Daum, N. Schierbaum, C. Falch, A. Kirschniak, T. E.
786 Schaffer and K. Schenke-Layland: Biomechanical and biomolecular characterization of
787 extracellular matrix structures in human colon carcinomas. *Matrix Biol*, 68-69, 180-193
788 (2018) doi:10.1016/j.matbio.2018.03.016
- 789 37. A. Zbinden, J. Marzi, K. Schlunder, C. Probst, M. Urbanczyk, S. Black, E. M.
790 Brauchle, S. L. Layland, U. Kraushaar, G. Duffy, K. Schenke-Layland and P. Loskill: Non-
791 invasive marker-independent high content analysis of a microphysiological human pancreas-
792 on-a-chip model. *Matrix Biol*, 85-86, 205-220 (2020) doi:10.1016/j.matbio.2019.06.008
- 793 38. J. Marzi, E. M. Brauchle, K. Schenke-Layland and M. W. Rolle: Non-invasive
794 functional molecular phenotyping of human smooth muscle cells utilized in cardiovascular
795 tissue engineering. *Acta Biomater*, 89, 193-205 (2019) doi:10.1016/j.actbio.2019.03.026
- 796 39. T. J. Stevenson, H. C. Murray, C. Turner, R. L. M. Faull, B. V. Dieriks and M. A.
797 Curtis: alpha-synuclein inclusions are abundant in non-neuronal cells in the anterior olfactory
798 nucleus of the Parkinson's disease olfactory bulb. *Sci Rep*, 10(1), 6682 (2020)
799 doi:10.1038/s41598-020-63412-x
- 800 40. H. Niu, L. Shen, T. Li, C. Ren, S. Ding, L. Wang, Z. Zhang, X. Liu, Q. Zhang, D.
801 Geng, X. Wu and H. Li: Alpha-synuclein overexpression in the olfactory bulb initiates

- 802 prodromal symptoms and pathology of Parkinson's disease. *Transl Neurodegener*, 7, 25
803 (2018) doi:10.1186/s40035-018-0128-6
- 804 41. M. Goedert: Alpha-synuclein and neurodegenerative diseases. *Nat Rev Neurosci*,
805 2(7), 492-501 (2001) doi:10.1038/35081564
- 806 42. R. L. Doty: Olfactory dysfunction in Parkinson disease. *Nat Rev Neurol*, 8(6), 329-39
807 (2012) doi:10.1038/nrneurol.2012.80
- 808 43. T. G. Beach, C. L. White, 3rd, C. L. Hladik, M. N. Sabbagh, D. J. Connor, H. A. Shill,
809 L. I. Sue, J. Sasse, J. Bachalakuri, J. Henry-Watson, H. Akiyama, C. H. Adler and C. Arizona
810 Parkinson's Disease: Olfactory bulb alpha-synucleinopathy has high specificity and sensitivity
811 for Lewy body disorders. *Acta Neuropathol*, 117(2), 169-74 (2009) doi:10.1007/s00401-008-
812 0450-7
- 813 44. D. Ebrahimi-Fakhari, L. Wahlster and P. J. McLean: Protein degradation pathways in
814 Parkinson's disease: curse or blessing. *Acta Neuropathol*, 124(2), 153-72 (2012)
815 doi:10.1007/s00401-012-1004-6
- 816 45. T. R. Sampson, J. W. Debelius, T. Thron, S. Janssen, G. G. Shastri, Z. E. Ilhan, C.
817 Challis, C. E. Schretter, S. Rocha, V. Gradinaru, M. F. Chesselet, A. Keshavarzian, K. M.
818 Shannon, R. Krajmalnik-Brown, P. Wittung-Stafshede, R. Knight and S. K. Mazmanian: Gut
819 Microbiota Regulate Motor Deficits and Neuroinflammation in a Model of Parkinson's
820 Disease. *Cell*, 167(6), 1469-1480 e12 (2016) doi:10.1016/j.cell.2016.11.018
- 821 46. H. Braak, K. Del Tredici, U. Rub, R. A. de Vos, E. N. Jansen Steur and E. Braak:
822 Staging of brain pathology related to sporadic Parkinson's disease. *Neurobiol Aging*, 24(2),
823 197-211 (2003)


824

a


bioRxiv preprint doi: <https://doi.org/10.1101/2021.02.02.429468>; this version posted February 23, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.



b



c



d




Fig. 1






Fig. 2


a



b



c



d






Fig. 3

a


bioRxiv preprint doi: <https://doi.org/10.1101/2021.02.02.429468>; this version posted February 3, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.




b



c



d



e




Fig. 4










Fig. 5

